Status:
RECRUITING
Pathogenic Variants in Genes Associated With Lung Adenocarcinoma
Lead Sponsor:
Oscar Gerardo Arrieta Rodríguez
Conditions:
Lung Adenocarcinoma
Eligibility:
All Genders
16-85 years
Brief Summary
The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma. The main questions it aims to answer are: 1. What is...
Detailed Description
This is an observational, descriptive, and longitudinal study. The sample size was calculated with a proportion difference formula for a known population, considering the Local Institutional Personal...
Eligibility Criteria
Inclusion
- Both sexes
- ≥ 16 years old, according the institutional protocols for new patients admittances.
- histologically confirmed lung adenocarcinoma (LUAD)
- Signed written informed consent form
- A life expectancy greater than 8 weeks.
- Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET).
Exclusion
- A sample of peripheral blood that is not accessible.
- Insufficient clinical pathological information in the electronic clinical record.
- Elimination Criteria:
- Withdrawal
- Insufficient DNA quality and quantity for genomic sequencing analyses.
- Lost of follow up
Key Trial Info
Start Date :
December 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2025
Estimated Enrollment :
332 Patients enrolled
Trial Details
Trial ID
NCT06181812
Start Date
December 15 2022
End Date
December 15 2025
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología
Mexico City, Mexico, 14080